BiotechTube
TrueRelief

TrueRelief

Boston, United States· Est.
truerelief.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

TrueRelief is a private medical device company commercializing a proprietary high-frequency electrical neuromodulation system for pain relief. Its core product is an FDA-cleared device that has demonstrated in a clinical trial a 47% reduction in opioid usage and improved pain scores in post-operative patients. The company targets the significant opioid crisis by offering a drug-free alternative for acute and chronic pain management through clinician-administered treatments. Its business model involves selling or leasing devices to healthcare providers and institutions.

Pain ManagementPost-operative Care

Technology Platform

Proprietary high-frequency (20,000 Hz) pulsed direct current neuromodulation delivered via dynamically directed stainless steel probes for non-invasive pain relief.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The urgent need to reduce opioid prescriptions creates a powerful policy and clinical tailwind for non-opioid alternatives.
The large and growing market for post-surgical and chronic pain management offers significant revenue potential if adoption is achieved.
Demonstrated clinical efficacy and federal grant funding provide validation to attract partners, customers, and further investment.

Risk Factors

Market adoption is challenging, requiring a shift in entrenched clinical practices and pain management protocols.
Securing consistent insurance reimbursement is critical for growth but can be a lengthy and uncertain process.
The company faces competition from other neuromodulation devices, pharmaceuticals, and digital health solutions in a crowded pain management landscape.

Competitive Landscape

TrueRelief competes in the neuromodulation and digital therapeutic space for pain management. Direct competitors include other prescription neuromodulation devices like SPR Therapeutics' Sprint PNS system and Nevro's HF10 therapy. It also competes broadly with pharmaceutical opioids and NSAIDs, as well as consumer-grade TENS units. Its key differentiators are its 20,000 Hz frequency, pulsed direct current, and clinician-administered probe delivery system.

More companies in Small Molecule Drugs →More companies in United States →